Research Reports

Key takeaways

Revenue was flat at $880M as volume declines in EDS and OIS offset growth in Wellspect and APAC.

Gross profit decreased 8.4% to $427M, with gross margin compressing to 48.5% due to lower volumes and higher tariff costs.

Operating income swung to a loss of $35M from a profit of $63M, driven by restructuring costs and tariff headwinds.

Net income turned negative at -$10M, with diluted EPS of -$0.05, compared to $0.10 in the prior year.

Operating cash flow surged to $40M from $7M, reflecting improved working capital management.

Full analysis

Revenue Flat Despite Mixed Segment Performance

Gross Margin Compression from Volume and Tariffs

Operating Loss Driven by Restructuring and Tariffs

Cash Flow Improvement and Capital Allocation Shift

Outlook and Risks

The company faces ongoing headwinds from global economic conditions, including uncertainties related to trade policies and inflation. The shift in distribution model is expected to increase variability in ordering patterns and contribute to fluctuations in net sales and operating income. Despite these challenges, the company remains focused on its strategic initiatives, including R&D investments and cost management under the 2026 Plan.

XRAY · DENTSPLY SIRONA Inc.